<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599339</url>
  </required_header>
  <id_info>
    <org_study_id>SP0854</org_study_id>
    <nct_id>NCT00599339</nct_id>
  </id_info>
  <brief_title>Transdermal Rotigotine User Surveillance Study</brief_title>
  <acronym>TRUST</acronym>
  <official_title>A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in an observational multiple-cohort design aimed at acquiring
      clinical, treatment, health status, and economic data. Patients with Parkinson's disease (PD)
      will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients attending the physician and fulfilling the eligibility criteria are included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33)</measure>
    <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
    <description>The Unified Parkinson's disease rating scale (UPDRS) Part III (Motor Examination) contains 31 questions. Each question ranges from 0 (best possible outcome) to 4 (worst outcome). The total score ranges from 0 (best possible outcome) to 124 (worst outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33)</measure>
    <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
    <description>The Unified Parkinson's disease rating scale (UPDRS) question 32 of part IV asks. &quot;What Proportion of the waking day are dyskinesias present?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 33 of Part IV at Visit 7 (Month 33)</measure>
    <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
    <description>The Unified Parkinson's disease rating scale (UPDRS) Part IV question 33 asks for complications of therapy in the past week, through the question &quot;How disabling are the dyskinesias ? &quot; Answers range from 0 (Not disabling) to 4 (Completely disabling).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 39 of Part IV at Visit 7 (Month 33)</measure>
    <time_frame>33 months</time_frame>
    <description>The Unified Parkinson's disease rating scale (UPDRS) Part IV question 39 asks &quot;What proportion of the waking day is the patient &quot;off&quot;, on average?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturnal Dystonia Cramp Score (NADCS) at Visit 7 (Month 33)</measure>
    <time_frame>33 months</time_frame>
    <description>The NADCS assesses sleep-related motor complaints including nocturnal akinesia, dystonia and painful cramps by an ordinal severity scale.
The NADCS total score ranges from 0 (normal) to 4 (maximum severity). NADCS value was missing for one subject at Visit 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoehn &amp; Yahr Stage at Visit 7 (Month 33)</measure>
    <time_frame>33 months</time_frame>
    <description>The Hoehn and Yahr staging of Parkinson's disease in the &quot;on&quot; stage, if applicable, had to be completed by the physician.
Possible staging:
0 No signs of disease
1 Unilateral disease
2 Bilateral disease without impairment of balance
3 Mild to moderate bilateral disease, some postural instability, physically dependent
4 Severe disability, still able to walk or stand unassisted
5 Wheelchair bound or bedridden unless aided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Adverse Events of Cardiac Valve Fibrosis During the Study (up to 33 Months)</measure>
    <time_frame>33 months</time_frame>
    <description>The analysis was performed for the non-disjunctive classification into patients at risk to develop an Adverse Event associated with Rotigotine and patients at risk to develop an Adverse Event not associated with Rotigotine.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">2195</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Neupro</arm_group_label>
    <description>Neupro at study onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dopamine Agonist</arm_group_label>
    <description>Other Dopamine-Agonist at study onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Dopa</arm_group_label>
    <description>L-Dopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neupro + L-Dopa</arm_group_label>
    <description>Neupro in combination with L-Dopa at study onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dopamine Agonist + L-Dopa</arm_group_label>
    <description>Other Dopamine Agonist in combination with L-Dopa at study onset</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with idiopathic early-stage Parkinson's Disease requiring dopaminergic
             monotherapy (rotigotine, other dopamine agonists or levodopa) at study onset

          -  Patients with advanced-stage Parkinson's Disease requiring dopaminergic therapy with
             levodopa in combination with rotigotine or other dopamine agonists at study onset

        Exclusion Criteria:

          -  Patients who are unable to comply with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>813</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>808</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>822</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>811</name>
      <address>
        <city>Litomysl</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>803</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>809</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>817</name>
      <address>
        <city>Pisek</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>814</name>
      <address>
        <city>Plzen-Lochotin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>829</name>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>805</name>
      <address>
        <city>Praha 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>825</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>804</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>832</name>
      <address>
        <city>Rakovnik</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>819</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>752</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>751</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>750</name>
      <address>
        <city>Sonderborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>242</name>
      <address>
        <city>Aalen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>143</name>
      <address>
        <city>Achim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>240</name>
      <address>
        <city>Alzenau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>145</name>
      <address>
        <city>Annaberg-Buchholz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>245</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>185</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>130</name>
      <address>
        <city>Bad Neustadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>131</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Berg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>102</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>119</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>142</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>150</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>157</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>163</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>166</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>195</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>198</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>206</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>207</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>224</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>243</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>127</name>
      <address>
        <city>Bielefield</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>178</name>
      <address>
        <city>Blankenburg (Harz)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>149</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>151</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>216</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>220</name>
      <address>
        <city>Brandenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>236</name>
      <address>
        <city>Butzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>237</name>
      <address>
        <city>Butzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203</name>
      <address>
        <city>Böblingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>133</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>199</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>232</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>219</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>112</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>141</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>129</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>162</name>
      <address>
        <city>Erbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>156</name>
      <address>
        <city>Friedberg (Hessen)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>247</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>223</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>249</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>167</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>121</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>140</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>176</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>217</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>241</name>
      <address>
        <city>Heidenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>138</name>
      <address>
        <city>Hemmoor</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>173</name>
      <address>
        <city>Herborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>214</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>181</name>
      <address>
        <city>Jülich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Karlstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106</name>
      <address>
        <city>Karlstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>244</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>124</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>153</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>179</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>175</name>
      <address>
        <city>Leutkirch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>152</name>
      <address>
        <city>Lutherstadt Eisleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>230</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>235</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>148</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>189</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>191</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>169</name>
      <address>
        <city>Naumburg (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>182</name>
      <address>
        <city>Neuburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>118</name>
      <address>
        <city>Oberhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>164</name>
      <address>
        <city>Oberursel (Taunus)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>171</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>196</name>
      <address>
        <city>Oranienburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114</name>
      <address>
        <city>Rheda-Wiedenbrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>188</name>
      <address>
        <city>Rottenburg am Neckar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>187</name>
      <address>
        <city>Schriesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>134</name>
      <address>
        <city>Singen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>229</name>
      <address>
        <city>Stadtroda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>180</name>
      <address>
        <city>Starnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>146</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>186</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>211</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>226</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>139</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>172</name>
      <address>
        <city>Unterhaching</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>239</name>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>233</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>122</name>
      <address>
        <city>Wolfach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>194</name>
      <address>
        <city>Zwickau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>607</name>
      <address>
        <city>Alexandroupoli</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>600</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>602</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>605</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>610</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>608</name>
      <address>
        <city>Chaidari</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>611</name>
      <address>
        <city>Marousi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>601</name>
      <address>
        <city>Melissia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>604</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>606</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>664</name>
      <address>
        <city>Acquaviva Delle Fonti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>654</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>665</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>655</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>666</name>
      <address>
        <city>Casarano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>662</name>
      <address>
        <city>Cassino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>653</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>661</name>
      <address>
        <city>Imperia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>650</name>
      <address>
        <city>Lido Di Camaiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>663</name>
      <address>
        <city>Lodi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>658</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>660</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>667</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>657</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>656</name>
      <address>
        <city>San Giovannni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>669</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>704</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>707</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>703</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>701</name>
      <address>
        <city>Mexico D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>702</name>
      <address>
        <city>Mexico D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>706</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>710</name>
      <address>
        <city>Morelia Michoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>708</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>705</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>425</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>406</name>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407</name>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>417</name>
      <address>
        <city>Bistrita</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>412</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>418</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>423</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>424</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>434</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>436</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>427</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>411</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>433</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>404</name>
      <address>
        <city>Drobeta Turnu Severin</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>437</name>
      <address>
        <city>Foscani, Jud. Vrancea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>405</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>420</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>403</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>409</name>
      <address>
        <city>Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>415</name>
      <address>
        <city>Medgidia</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>402</name>
      <address>
        <city>Orastie</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401</name>
      <address>
        <city>Pitesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>428</name>
      <address>
        <city>Pitesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>422</name>
      <address>
        <city>Resista</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>435</name>
      <address>
        <city>Rm. Valcea Jud. Valcea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>408</name>
      <address>
        <city>Satu Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>413</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>429</name>
      <address>
        <city>St. Gheorghe</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>416</name>
      <address>
        <city>Targoviste</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>432</name>
      <address>
        <city>TG. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>414</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>421</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>521</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>500</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>507</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>514</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>501</name>
      <address>
        <city>Dolni Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>505</name>
      <address>
        <city>Dubnica Nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>522</name>
      <address>
        <city>Krompachy</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>520</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>508</name>
      <address>
        <city>Skalica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>503</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>509</name>
      <address>
        <city>Stara Lubovna</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>510</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>519</name>
      <address>
        <city>Vranov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>516</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>518</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308</name>
      <address>
        <city>Alzira (Valencia)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>320</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>305</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>318</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>315</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>313</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>307</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>314</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>312</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>355</name>
      <address>
        <city>Biel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>353</name>
      <address>
        <city>Sargans</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>354</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>351</name>
      <address>
        <city>Tschugg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>350</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <results_first_submitted>April 10, 2015</results_first_submitted>
  <results_first_submitted_qc>April 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>Neupro</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Rotigotine</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll subjects in June 2006. Overall, 2195 patients were enrolled in this study (Enrolled Set [ES]), of which 2179 were treated with rotigotine or another Parkinson's disease treatment according to the study protocol at least once (Safety Set [SS]).</recruitment_details>
      <pre_assignment_details>There were 36 patients without valid data consent. Therefore only Safety data were analyzed for these 36 patients.
Patients without valid data consent or an unknown study termination status were neither considered as completer nor as non-completer in the Clinical Study Report. These patients are considered as non-completers in the summary below.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall</title>
          <description>For this study, 5 groups of patients with different Parkinson's disease treatments were to be considered. Initial treatments were to include dopaminergic monotherapy with rotigotine, other dopamine agonists (eg, pramipexole, cabergoline, ropinirole), or L-dopa, treatment with L-dopa combined with rotigotine or other dopamine agonists. Treatment was to be performed according to standard medical practice. Patients were to be given a treatment for Parkinson's disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="2179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1531"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="664"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No valid data consent</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Termination Status Unknown</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characterisitcs refer to the Enrolled Set [ES]. 2195 patients were enrolled in this study, of which 36 patients had no valid data consent. Data from these patients were not used for analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>For this study, 5 groups of patients with different Parkinson’s disease treatments were to be considered. Initial treatments were to include dopaminergic monotherapy with rotigotine, other dopamine agonists (eg, pramipexole, cabergoline, ropinirole), or L-dopa, treatment with L-dopa combined with rotigotine or other dopamine agonists. Treatment was to be performed according to standard medical practice. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33)</title>
        <description>The Unified Parkinson’s disease rating scale (UPDRS) Part III (Motor Examination) contains 31 questions. Each question ranges from 0 (best possible outcome) to 4 (worst outcome). The total score ranges from 0 (best possible outcome) to 124 (worst outcome).</description>
        <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33)</title>
          <description>The Unified Parkinson’s disease rating scale (UPDRS) Part III (Motor Examination) contains 31 questions. Each question ranges from 0 (best possible outcome) to 4 (worst outcome). The total score ranges from 0 (best possible outcome) to 124 (worst outcome).</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="233"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="400"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="377"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="35"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="14.7"/>
                    <measurement group_id="O2" value="-2.5" spread="10.3"/>
                    <measurement group_id="O3" value="-2.2" spread="11.1"/>
                    <measurement group_id="O4" value="-5.6" spread="16.9"/>
                    <measurement group_id="O5" value="0.2" spread="13.2"/>
                    <measurement group_id="O6" value="0.0" spread="12.2"/>
                    <measurement group_id="O7" value="-1.2" spread="13.8"/>
                    <measurement group_id="O8" value="3.5" spread="6.4"/>
                    <measurement group_id="O9" value="-1.2" spread="14.2"/>
                    <measurement group_id="O10" value="-1.5" spread="17.5"/>
                    <measurement group_id="O11" value="-2.5" spread="13.9"/>
                    <measurement group_id="O12" value="8.6" spread="13.5"/>
                    <measurement group_id="O13" value="1.5" spread="14.7"/>
                    <measurement group_id="O14" value="20.0" spread="29.7"/>
                    <measurement group_id="O15" value="-3.2" spread="10.8"/>
                    <measurement group_id="O16" value="4.1" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33)</title>
        <description>The Unified Parkinson’s disease rating scale (UPDRS) question 32 of part IV asks. &quot;What Proportion of the waking day are dyskinesias present?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
        <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33)</title>
          <description>The Unified Parkinson’s disease rating scale (UPDRS) question 32 of part IV asks. &quot;What Proportion of the waking day are dyskinesias present?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="233"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="400"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="377"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="35"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.6"/>
                    <measurement group_id="O3" value="-0.1" spread="0.5"/>
                    <measurement group_id="O4" value="0.0" spread="0.8"/>
                    <measurement group_id="O5" value="0.1" spread="0.8"/>
                    <measurement group_id="O6" value="-0.1" spread="0.5"/>
                    <measurement group_id="O7" value="-0.1" spread="0.5"/>
                    <measurement group_id="O8" value="0.0" spread="0.0"/>
                    <measurement group_id="O9" value="0.1" spread="0.7"/>
                    <measurement group_id="O10" value="0.2" spread="1.0"/>
                    <measurement group_id="O11" value="0.2" spread="0.7"/>
                    <measurement group_id="O12" value="0.2" spread="0.6"/>
                    <measurement group_id="O13" value="0.2" spread="0.7"/>
                    <measurement group_id="O14" value="0.5" spread="0.7"/>
                    <measurement group_id="O15" value="-0.2" spread="0.4"/>
                    <measurement group_id="O16" value="0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 33 of Part IV at Visit 7 (Month 33)</title>
        <description>The Unified Parkinson’s disease rating scale (UPDRS) Part IV question 33 asks for complications of therapy in the past week, through the question “How disabling are the dyskinesias ? “ Answers range from 0 (Not disabling) to 4 (Completely disabling).</description>
        <time_frame>From Baseline to Visit 7 (Month 33)</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 33 of Part IV at Visit 7 (Month 33)</title>
          <description>The Unified Parkinson’s disease rating scale (UPDRS) Part IV question 33 asks for complications of therapy in the past week, through the question “How disabling are the dyskinesias ? “ Answers range from 0 (Not disabling) to 4 (Completely disabling).</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="233"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="400"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="377"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="35"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.4"/>
                    <measurement group_id="O3" value="-0.1" spread="0.4"/>
                    <measurement group_id="O4" value="-0.1" spread="0.7"/>
                    <measurement group_id="O5" value="0.0" spread="0.8"/>
                    <measurement group_id="O6" value="-0.0" spread="0.7"/>
                    <measurement group_id="O7" value="-0.1" spread="0.6"/>
                    <measurement group_id="O8" value="0.0" spread="0.0"/>
                    <measurement group_id="O9" value="0.0" spread="0.7"/>
                    <measurement group_id="O10" value="0.0" spread="0.6"/>
                    <measurement group_id="O11" value="0.1" spread="0.7"/>
                    <measurement group_id="O12" value="-0.1" spread="0.7"/>
                    <measurement group_id="O13" value="0.2" spread="0.8"/>
                    <measurement group_id="O14" value="0.0" spread="0.0"/>
                    <measurement group_id="O15" value="-0.1" spread="0.3"/>
                    <measurement group_id="O16" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 39 of Part IV at Visit 7 (Month 33)</title>
        <description>The Unified Parkinson’s disease rating scale (UPDRS) Part IV question 39 asks “What proportion of the waking day is the patient &quot;off&quot;, on average?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
        <time_frame>33 months</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 39 of Part IV at Visit 7 (Month 33)</title>
          <description>The Unified Parkinson’s disease rating scale (UPDRS) Part IV question 39 asks “What proportion of the waking day is the patient &quot;off&quot;, on average?&quot; Answers range from 0 (None) to 4 (76-100 % of the day).</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="233"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="400"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="377"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="35"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.9"/>
                    <measurement group_id="O2" value="0.5" spread="0.9"/>
                    <measurement group_id="O3" value="-0.1" spread="0.8"/>
                    <measurement group_id="O4" value="0.1" spread="0.9"/>
                    <measurement group_id="O5" value="0.1" spread="0.9"/>
                    <measurement group_id="O6" value="0.1" spread="1.1"/>
                    <measurement group_id="O7" value="-0.4" spread="0.9"/>
                    <measurement group_id="O8" value="0.0" spread="0.0"/>
                    <measurement group_id="O9" value="0.0" spread="0.8"/>
                    <measurement group_id="O10" value="0.0" spread="0.0"/>
                    <measurement group_id="O11" value="0.2" spread="0.9"/>
                    <measurement group_id="O12" value="0.2" spread="0.9"/>
                    <measurement group_id="O13" value="-0.0" spread="1.0"/>
                    <measurement group_id="O14" value="1.5" spread="2.1"/>
                    <measurement group_id="O15" value="0.0" spread="0.4"/>
                    <measurement group_id="O16" value="0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturnal Dystonia Cramp Score (NADCS) at Visit 7 (Month 33)</title>
        <description>The NADCS assesses sleep-related motor complaints including nocturnal akinesia, dystonia and painful cramps by an ordinal severity scale.
The NADCS total score ranges from 0 (normal) to 4 (maximum severity). NADCS value was missing for one subject at Visit 7.</description>
        <time_frame>33 months</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturnal Dystonia Cramp Score (NADCS) at Visit 7 (Month 33)</title>
          <description>The NADCS assesses sleep-related motor complaints including nocturnal akinesia, dystonia and painful cramps by an ordinal severity scale.
The NADCS total score ranges from 0 (normal) to 4 (maximum severity). NADCS value was missing for one subject at Visit 7.</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="232"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="400"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="376"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="34"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="1.79"/>
                    <measurement group_id="O2" value="1.36" spread="3.51"/>
                    <measurement group_id="O3" value="-0.15" spread="1.48"/>
                    <measurement group_id="O4" value="0.05" spread="2.53"/>
                    <measurement group_id="O5" value="-0.09" spread="1.84"/>
                    <measurement group_id="O6" value="-0.26" spread="2.30"/>
                    <measurement group_id="O7" value="-0.73" spread="1.49"/>
                    <measurement group_id="O8" value="0.75" spread="1.06"/>
                    <measurement group_id="O9" value="-0.03" spread="2.06"/>
                    <measurement group_id="O10" value="-0.42" spread="2.01"/>
                    <measurement group_id="O11" value="-0.03" spread="2.07"/>
                    <measurement group_id="O12" value="1.05" spread="1.39"/>
                    <measurement group_id="O13" value="-0.01" spread="1.90"/>
                    <measurement group_id="O14" value="3.25" spread="4.60"/>
                    <measurement group_id="O15" value="-0.38" spread="1.10"/>
                    <measurement group_id="O16" value="0.22" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hoehn &amp; Yahr Stage at Visit 7 (Month 33)</title>
        <description>The Hoehn and Yahr staging of Parkinson’s disease in the “on” stage, if applicable, had to be completed by the physician.
Possible staging:
0 No signs of disease
1 Unilateral disease
2 Bilateral disease without impairment of balance
3 Mild to moderate bilateral disease, some postural instability, physically dependent
4 Severe disability, still able to walk or stand unassisted
5 Wheelchair bound or bedridden unless aided</description>
        <time_frame>33 months</time_frame>
        <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Neupro Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O2">
            <title>Neupro Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro at Baseline.</description>
          </group>
          <group group_id="O3">
            <title>Other Dopamine Agonist (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O4">
            <title>Other Dopamine Agonist (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist at Baseline.</description>
          </group>
          <group group_id="O5">
            <title>L-Dopa Monotherapy (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O6">
            <title>L-Dopa Monotherapy (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with L-Dopa at Baseline.</description>
          </group>
          <group group_id="O7">
            <title>Multiple Dopamine Agonists (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O8">
            <title>Multiple Dopamine Agonists (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists at Baseline.</description>
          </group>
          <group group_id="O9">
            <title>Neupro + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O10">
            <title>Neupro + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with Neupro and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with Neupro and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O11">
            <title>Other Dopamine Agonist + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O12">
            <title>Other Dopamine Agonist + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with other dopamine agonist and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with other dopamine agonist and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O13">
            <title>Multiple Dopamine Agonists + L-Dopa (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O14">
            <title>Multiple Dopamine Agonists + L-Dopa (&lt; 3 Months)</title>
            <description>This group shows all subjects which were treated with multiple dopamine agonists and L-Dopa for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily treated with multiple dopamine agonists and L-Dopa at Baseline.</description>
          </group>
          <group group_id="O15">
            <title>Not Treated (&gt;= 3 Months)</title>
            <description>This group shows all subjects which were not treated for 3 months or more at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
          <group group_id="O16">
            <title>Not Treated (&lt; 3 Months)</title>
            <description>This group shows all subjects which were not treated for less than 3 months at Visit 7. Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.
Thus, subjects presented in this group weren't necessarily not treated at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Hoehn &amp; Yahr Stage at Visit 7 (Month 33)</title>
          <description>The Hoehn and Yahr staging of Parkinson’s disease in the “on” stage, if applicable, had to be completed by the physician.
Possible staging:
0 No signs of disease
1 Unilateral disease
2 Bilateral disease without impairment of balance
3 Mild to moderate bilateral disease, some postural instability, physically dependent
4 Severe disability, still able to walk or stand unassisted
5 Wheelchair bound or bedridden unless aided</description>
          <population>All enrolled and treated patients, having at least one valid on-treatment measurement in any efficacy variable are included in the Full Analysis Set (FAS).
Patients were to be given a treatment for Parkinson’s disease deemed appropriate by the physician, and the treatment could be modified by the physician at any time during the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="234"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="401"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="378"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="36"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="13"/>
                <count group_id="O16" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="37"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="4"/>
                    <measurement group_id="O16" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="118"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="186"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="192"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="15"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="7"/>
                    <measurement group_id="O16" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="131"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="119"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="13"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="46"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="24"/>
                    <measurement group_id="O12" value="4"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data/Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Adverse Events of Cardiac Valve Fibrosis During the Study (up to 33 Months)</title>
        <description>The analysis was performed for the non-disjunctive classification into patients at risk to develop an Adverse Event associated with Rotigotine and patients at risk to develop an Adverse Event not associated with Rotigotine.</description>
        <time_frame>33 months</time_frame>
        <population>For analysis of Safety the patients in the Safety Set were sub-grouped into patients at risk developing an Adverse Event (AE) associated with rotigotine and patients at risk developing an AE not associated with rotigotine. This sub-grouping is non-disjunctive in nature, i.e. one patient might fall into both subgroups.</population>
        <group_list>
          <group group_id="O1">
            <title>Associated With Rotigotine</title>
            <description>A patient was analyzed related to Adverse Events (AEs) associated with Rotigotine only if during the study he was at risk to develop an AE associated with Rotigotine.
An Adverse Event was considered to be associated with Rotigotine if Rotigotine was administered at least once within 30 days prior to the onset of the adverse event. &quot;Associated Event&quot; does not necessarily mean related to treatment with Rotigotine.</description>
          </group>
          <group group_id="O2">
            <title>Not Associated With Rotigotine</title>
            <description>A patient was analyzed related to Adverse Events (AEs) not associated with Rotigotine only if during the study he was at risk to develop an AE not associated with Rotigotine.
An adverse event was considered not to be associated with Rotigotine, if no Rotigotine was administered in the 30 days period prior to the onset of the AE.</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Adverse Events of Cardiac Valve Fibrosis During the Study (up to 33 Months)</title>
          <description>The analysis was performed for the non-disjunctive classification into patients at risk to develop an Adverse Event associated with Rotigotine and patients at risk to develop an Adverse Event not associated with Rotigotine.</description>
          <population>For analysis of Safety the patients in the Safety Set were sub-grouped into patients at risk developing an Adverse Event (AE) associated with rotigotine and patients at risk developing an AE not associated with rotigotine. This sub-grouping is non-disjunctive in nature, i.e. one patient might fall into both subgroups.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1390"/>
                <count group_id="O2" value="1328"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac valve disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac valve sclerosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aortic valve sclerosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected during the course of the study from Baseline (Visit 1) up to Visit 7 (Month 33 ± 30 days).</time_frame>
      <desc>For analysis of Safety the patients in the Safety Set were sub-grouped into patients at risk developing an Adverse Event (AE) associated with rotigotine and patients at risk developing an AE not associated with rotigotine. This sub-grouping is non-disjunctive in nature, i.e. one patient might fall into both subgroups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Associated With Rotigotine</title>
          <description>A patient was analyzed related to Adverse Events (AEs) associated with Rotigotine only if during the study he was at risk to develop an AE associated with Rotigotine.
An Adverse Event was considered to be associated with Rotigotine if Rotigotine was administered at least once within 30 days prior to the onset of the adverse event. &quot;Associated Event&quot; does not necessarily mean related to treatment with Rotigotine.</description>
        </group>
        <group group_id="E2">
          <title>Not Associated With Rotigotine</title>
          <description>A patient was analyzed related to Adverse Events (AEs) not associated with Rotigotine only if during the study he was at risk to develop an AE not associated with Rotigotine.
An adverse event was considered not to be associated with Rotigotine, if no Rotigotine was administered in the 30 days period prior to the onset of the AE.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="1390"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1390"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Atrioventricular block third degree</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acromegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Laryngotracheo bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Norwalk virus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mycotoxicosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1390"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pharyngeal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vertebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus non-insulin-dependent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Starvation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1390"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Posture abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1390"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Osteosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colon cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastric cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Genital neoplasm malignant female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Meningeal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of conjunctiva</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gammopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="47" subjects_affected="39" subjects_at_risk="1390"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1390"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cerebellar haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1390"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Progressive supranuclear palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cerebral hypoperfusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Multiple system atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Fine motor delay</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pseudoradicular syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Spinal cord haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Phrenic nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Myoclonic epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sleep attacks</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cyclothymic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Binge eating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Impulse-control disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypersexuality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Therapy regimen changed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Device therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Drug therapy changed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Deep brain stimulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1390"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1390"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="1390"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="120" subjects_affected="105" subjects_at_risk="1390"/>
                <counts group_id="E2" events="101" subjects_affected="85" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="76" subjects_affected="67" subjects_at_risk="1390"/>
                <counts group_id="E2" events="82" subjects_affected="77" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="60" subjects_affected="49" subjects_at_risk="1390"/>
                <counts group_id="E2" events="79" subjects_affected="67" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="55" subjects_affected="54" subjects_at_risk="1390"/>
                <counts group_id="E2" events="74" subjects_affected="72" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493 (UCB)</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

